Literature DB >> 20970406

Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.

Katherine Ann Scott1, John Barnes, Roger Clive Whitehead, Ian James Stratford, Karen Ann Nolan.   

Abstract

The enzyme NAD(P)H quinone oxidoreductase (NQO1) can function both as a detoxifying enzyme as well as chaperone protein. The latter property has been extensively characterized by the use of dicoumarol which inhibits the chaperone properties of NQO1 in cells. However, the use of this compound is compromised by its multiple "off-target" effects. Coumarin-based compounds that are more potent than dicoumarol as inhibitors of NQO1 in cells have been identified (Nolan et al., Biochem Pharmacol 2010;80:977-81). The purpose of the work reported here is to evaluate the off-target effects of these compounds when compared to dicoumarol. A range of these substituted coumarins are identified that are significantly less toxic than dicoumarol in a panel of nine cell lines. Further a number of the compounds generate much less intracellular superoxide, and many of them also show a reduced ability to induce apoptosis when compared to dicoumarol. None of these effects correlate with the ability of the compounds to inhibit the enzymatic activity of NQO1 in cells. In conclusion, potent inhibitors of NQO1 have been identified that will be more pharmacologically useful than dicoumarol for probing the function of NQO1 in cells and tissues.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970406     DOI: 10.1016/j.bcp.2010.10.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Activation of NQO-1 mediates the augmented contractions of isolated arteries due to biased activity of soluble guanylyl cyclase in their smooth muscle.

Authors:  Charlotte M S Detremmerie; Susan W S Leung; Paul M Vanhoutte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-30       Impact factor: 3.000

2.  Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells.

Authors:  Siriwoot Butsri; Veerapol Kukongviriyapan; Laddawan Senggunprai; Sarinya Kongpetch; Ponsilp Zeekpudsa; Auemduan Prawan
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

3.  NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.

Authors:  Joshua P Gray; Shpetim Karandrea; Delaine Zayasbazan Burgos; Anil A Jaiswal; Emma A Heart
Journal:  Toxicol Lett       Date:  2016-08-21       Impact factor: 4.372

4.  In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling.

Authors:  Karen A Nolan; Mark S Dunstan; Mary C Caraher; Katherine A Scott; David Leys; Ian J Stratford
Journal:  Mol Cancer Ther       Date:  2011-11-16       Impact factor: 6.261

Review 5.  Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1.

Authors:  Eduardo Salido; David J Timson; Isabel Betancor-Fernández; Rogelio Palomino-Morales; Ernesto Anoz-Carbonell; Juan Luis Pacheco-García; Milagros Medina; Angel L Pey
Journal:  J Pers Med       Date:  2022-05-05

6.  The effect of aging on acetaminophen pharmacokinetics, toxicity and Nrf2 in Fischer 344 rats.

Authors:  John Mach; Aniko Huizer-Pajkos; Victoria C Cogger; Catriona McKenzie; David G Le Couteur; Brett E Jones; Rafael de Cabo; Sarah N Hilmer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-07-17       Impact factor: 6.053

7.  Following anticancer drug activity in cell lysates with DNA devices.

Authors:  Dimithree Kahanda; Naveen Singh; David A Boothman; Jason D Slinker
Journal:  Biosens Bioelectron       Date:  2018-07-30       Impact factor: 12.545

Review 8.  Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective.

Authors:  Sachin Sharma; Arshdeep Singh; Sahil Sharma; Ram Sharma; Jagjeet Singh; Nihar Kinarivala; Kunal Nepali; Jing P Liou
Journal:  Anticancer Agents Med Chem       Date:  2021       Impact factor: 2.527

9.  Mitochondrial function in human neuroblastoma cells is up-regulated and protected by NQO1, a plasma membrane redox enzyme.

Authors:  Jiyeong Kim; Su-Kyung Kim; Hwa-Kyung Kim; Mark P Mattson; Dong-Hoon Hyun
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240

10.  Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis.

Authors:  Qing Li; Ahmad F Karim; Xuedong Ding; Biswajit Das; Curtis Dobrowolski; Richard M Gibson; Miguel E Quiñones-Mateu; Jonathan Karn; Roxana E Rojas
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.